Pills masthead

Archives: Search / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008200720062004

 
From
To
Jun 1, 2022
LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule Topline Results Expected Later This Year...

More
May 12, 2022
LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year -- PHILADELPHIA, May 12,...

More
May 4, 2022
LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of...

More
Apr 27, 2022
LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management...

More
Mar 29, 2022
LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa., March 29, 2022 /PRNewswire/ --...

More
Mar 18, 2022
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 14, 2022, notifying the company that it is not in...

More
Mar 4, 2022
LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14

Lannett Company, Inc. (NYSE: LCI) today announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at 12:30 p.m. PT at The Ritz Carlton, in...

More
Mar 4, 2022
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 2, 2022, notifying the company that it is not in...

More
Mar 4, 2022
LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Carmel, NY, as well as equipment located...

More
Feb 3, 2022
LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021. "For the quarter, ongoing and increasing competitive pricing pressure...

More
Jan 27, 2022
LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, after the market closes. Lannett...

More
Jan 21, 2022
LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New...

More
Dec 20, 2021
Lannett Announces Submission of Investigational New Drug (IND) Application For Biosimilar Insulin Glargine

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of...

More
Nov 3, 2021
Lannett Reports Fiscal 2022 First-Quarter Financial Results; Revises Down Full-year Guidance

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 first quarter ended September 30, 2021. "For the quarter, solid sales of several key products contributed to...

More
Oct 28, 2021
Lannett To Report Fiscal 2022 First-quarter Financial Results, Host Conference Call On Wednesday, November 3

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 first quarter on Wednesday, November 3, 2021, after the market closes. Lannett...

More
Aug 30, 2021
Lannett Commences Marketing Mycophenolate Mofetil For Oral Suspension

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally developed product. Total U.S. sales of...

More
Aug 25, 2021
Lannett Announces Fiscal 2021 Fourth-Quarter, Full-Year Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 fourth quarter and full year ended June 30, 2021. "With the recently signed agreement to be the exclusive...

More
Aug 18, 2021
Lannett To Report Fiscal 2021 Fourth-quarter, Full-year Financial Results, Host Conference Call On Wednesday, August 25

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 fourth quarter and full year on Wednesday, August 25, 2021, after the market closes....

More
Jul 29, 2021
LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler®...

More
Jul 12, 2021
Lannett Launches Fluvastatin Sodium ER Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product. Total U.S. sales of Fluvastatin Sodium...

More
Jun 1, 2021
Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing

Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol...

More
May 5, 2021
Lannett Announces Fiscal 2021 Third-Quarter Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. "In recent months, we have significantly advanced a number of strategic...

More
Apr 28, 2021
Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management...

More
Apr 22, 2021
Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility

Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to...

More
Apr 9, 2021
Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026

Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a...

More
1-25      26-50      51-75      76-100      101-125      126-150      151-175      176-200      201-225      226-250      251-275      276-300      301-325      326-350      351-375      376-400      401-425      426-450      451-475      476-500      501-525      526-550      551-575      576-600      601-625      626-650      651-675      676-694
Price Data
NYSELCI